Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.36 EPS, expectations were $-0.29.
Karyopharm Therapeutics Inc. (KPTI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 65,976,000 | $32,987,982 | 1.21% | ||
| 2. | 31,500,000 | $15,907,500 | +4% | 0.64% | |
| 3. | 25,000,000 | $12,249,993 | 0.28% | ||
| 4. | Avidity Partners Management David Witzke And Michael Gregory | 8,298,570 | $7,178,263 | 0.26% | |
| 5. | Palo Alto Investors William Leland Edwards | 5,102,193 | $4,413,397 | -11% | 0.39% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.22 | 41,140 | 45,140 | 2023-09-12 | Filing | ||
| $8.60 | 23,250 | Officer | 131,802 | 2021-05-07 | Filing | |
| $7.82 | 4,000 | Director | 4,000 | 2021-05-06 | Filing | |
| $14.54 | 7,500 | Officer | 7,500 | 2020-08-26 | Filing | |
| $33.00 | 2,000 | Officer | 3,000 | 2015-04-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.17 | 6,789 | 342,931 | 2024-04-22 | Filing | ||
| $1.29 | 3,563 | 1,157,273 | 2024-04-04 | Filing | ||
| $1.30 | 3,573 | 1,160,836 | 2024-03-05 | Filing | ||
| $1.20 | 5,969 | 349,720 | 2024-03-01 | Filing | ||
| $1.17 | 15,667 | 355,689 | 2024-02-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,071,677 | $8,712,001 | 0% | |
| 2. | 8,710,158 | $7,534,287 | 0% | |
| 3. | 7,500,000 | $3,749,998 | 0.01% | |
| 4. | 2,382,428 | $2,061,034 | 0% | |
| 5. | 2,053,773 | $1,776,514 | 0% |
News See All
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call Transcript
Operator: Good morning. My name is Guru and I will be your conference operator today.
11 Best Biotech Penny Stocks to Buy Now
As investors begin to see light at the end of the tunnel, their risk appetite, which had vanished amid recession risks and volatility, is coming back, creating chances of major investments in high-risk...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2023 Earnings Call Transcript
Operator: Good morning. My name is Jason and I will be your conference operator today.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2023 Earnings Call Transcript
Operator: Good morning. My name is Ryan, and I will be your conference operator today.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2022 Earnings Call Transcript
Operator: Good day. My name is Andrea, and I will be your conference operator today.
5 Best Medical Stocks Under $5
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company that is involved in the development of drugs for advanced blood cancers.
Karyopharm Therapeutics Inc (KPTI): Are Hedge Funds Right About This Stock?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
Is KPTI A Good Stock To Buy According To Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
